Oakmont Partners LLC boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 46.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,356 shares of the medical instruments supplier’s stock after buying an additional 2,341 shares during the period. Oakmont Partners LLC’s holdings in Becton, Dickinson and were worth $1,435,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Guardian Life Insurance Co. of America increased its position in shares of Becton, Dickinson and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock worth $150,000 after buying an additional 6 shares during the period. Wellington Shields & Co. LLC increased its position in shares of Becton, Dickinson and by 0.3% in the first quarter. Wellington Shields & Co. LLC now owns 2,534 shares of the medical instruments supplier’s stock worth $465,000 after buying an additional 8 shares during the period. Parkside Financial Bank & Trust increased its position in shares of Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares during the period. North Star Investment Management Corp. increased its position in shares of Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 18 shares during the period. Finally, Investment Centers of America Inc. increased its position in shares of Becton, Dickinson and by 0.6% in the first quarter. Investment Centers of America Inc. now owns 3,922 shares of the medical instruments supplier’s stock worth $721,000 after buying an additional 22 shares during the period. Hedge funds and other institutional investors own 75.57% of the company’s stock.

Becton, Dickinson and Company (NYSE BDX) traded up 0.16% during trading on Friday, hitting $198.18. The company had a trading volume of 353,163 shares. The stock has a market capitalization of $45.10 billion, a PE ratio of 57.39 and a beta of 1.05. The stock has a 50-day moving average of $199.96 and a 200-day moving average of $189.27. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. During the same period in the prior year, the firm earned $2.35 EPS. The company’s revenue was down 5.1% compared to the same quarter last year. On average, equities analysts anticipate that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be given a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.48%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is currently 83.43%.

TRADEMARK VIOLATION WARNING: “Oakmont Partners LLC Purchases 2,341 Shares of Becton, Dickinson and Company (BDX)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/25/oakmont-partners-llc-purchases-2341-shares-of-becton-dickinson-and-company-bdx.html.

A number of brokerages have commented on BDX. Barclays PLC restated an “equal weight” rating and issued a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub downgraded Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research downgraded Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, May 4th. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Cowen and Company reiterated an “outperform” rating and set a $230.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Becton, Dickinson and presently has an average rating of “Buy” and an average price target of $195.79.

In other news, insider Gary M. Cohen sold 15,044 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $200.43, for a total transaction of $3,015,268.92. Following the completion of the transaction, the insider now directly owns 95,270 shares of the company’s stock, valued at approximately $19,094,966.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Nabil Shabshab sold 6,149 shares of the stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $201.76, for a total transaction of $1,240,622.24. Following the transaction, the insider now directly owns 15,648 shares of the company’s stock, valued at $3,157,140.48. The disclosure for this sale can be found here. Insiders have sold a total of 48,605 shares of company stock valued at $9,718,986 over the last three months. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.